Co-treatment of anti-CD19 CAR T cells with lenzilumab prevented CRS and reduced neuroinflammation in a special patient acute lymphoblastic leukemia xenograft model without impairing CAR T cell function [114]. The gene discussed is CD19; the disease is congenital rubella syndrome.